2005
DOI: 10.1016/j.jtcvs.2004.12.047
|View full text |Cite
|
Sign up to set email alerts
|

Midterm clinical result of tissue-engineered vascular autografts seeded with autologous bone marrow cells

Abstract: Biodegradable conduits or patches seeded with autologous bone marrow cells showed normal function (good patency to a maximum follow-up of 32 months). As living tissues, these vascular structures may have the potential for growth, repair, and remodeling. The tissue-engineering approach may provide an important alternative to the use of prosthetic materials in the field of pediatric cardiovascular surgery. Longer follow-up is necessary to confirm the durability of this approach.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

3
352
0
4

Year Published

2008
2008
2023
2023

Publication Types

Select...
6
2

Relationship

1
7

Authors

Journals

citations
Cited by 523 publications
(374 citation statements)
references
References 23 publications
3
352
0
4
Order By: Relevance
“…Ongoing clinical studies evaluating BMC-seeded grafts as venous conduits for congenital heart surgery report excellent safety profiles and 100% patency rates at 1-3 years of follow-up (6-8). Additionally, these grafts demonstrate growth potential, suggesting they may be more effective for the pediatric patient population than currently available vascular grafts (8,9).Although the functional efficacy and clinical utility of TEVGs are promising, little is known about how these BMC-seeded polyester tubes transform into living blood vessels in host recipients. It has been proposed that stem cells within the seeded BMC population differentiate into the endothelial cells (ECs) and smooth muscle cells (SMCs) of the developing neovessel, ultimately replacing the degrading polyester tube (10).…”
mentioning
confidence: 99%
See 2 more Smart Citations
“…Ongoing clinical studies evaluating BMC-seeded grafts as venous conduits for congenital heart surgery report excellent safety profiles and 100% patency rates at 1-3 years of follow-up (6-8). Additionally, these grafts demonstrate growth potential, suggesting they may be more effective for the pediatric patient population than currently available vascular grafts (8,9).Although the functional efficacy and clinical utility of TEVGs are promising, little is known about how these BMC-seeded polyester tubes transform into living blood vessels in host recipients. It has been proposed that stem cells within the seeded BMC population differentiate into the endothelial cells (ECs) and smooth muscle cells (SMCs) of the developing neovessel, ultimately replacing the degrading polyester tube (10).…”
mentioning
confidence: 99%
“…Ongoing clinical studies evaluating BMC-seeded grafts as venous conduits for congenital heart surgery report excellent safety profiles and 100% patency rates at 1-3 years of follow-up (6-8). Additionally, these grafts demonstrate growth potential, suggesting they may be more effective for the pediatric patient population than currently available vascular grafts (8,9).…”
mentioning
confidence: 99%
See 1 more Smart Citation
“…Tantamount to the successful treatment of these patients is our ability to generate new tissue for use in reconstructive surgical procedures. We currently possess the ability to create TEVGs with growth potential to be used as conduits in surgeries, such as the Fontan procedure [2,33], but the technology is still limited by stenosis development. An understanding of the molecular mechanisms driving neotissue formation in our graft will provide strategies to better direct this process, thereby abrogating the development of stenosis and leading to the development of a second-generation graft ready for widespread clinical application.…”
Section: Future Perspectivementioning
confidence: 99%
“…Un des objectifs majeurs de ces constructions hybrides est en effet de présenter, à terme, au contact du sang, une surface cellulaire non thrombogène [51]. En ingénierie vasculaire, des résultats cliniques probants sont rapportés avec des biomatériaux (dégradables ou non) associés -préa-lablement à leur implantation -à des cellules autologues dans la réalisation de pontages [34], de constructions vasculaires totalement autologues [35], ou dans la chirurgie des cardiopathies congénitales [36]. Selon les cas, les cellules ensemencées sont soit matures soit immatures et, dans ce cas, elles se différencieront in situ .…”
Section: Différenciation Des Csm Vers Le Lignage Ostéogéniqueunclassified